Truist Financial Initiates Coverage on Gilead Sciences (NASDAQ:GILD)

Investment analysts at Truist Financial started coverage on shares of Gilead Sciences (NASDAQ:GILD) in a note issued to investors on Monday. The firm set a “buy” rating and a $140.00 price target on the biopharmaceutical company’s stock. Truist Financial’s target price indicates a potential upside of 10.45% from the company’s current price.

GILD has been the topic of a number of other research reports. Mizuho increased their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a report on Friday, October 31st. Rothschild & Co Redburn lifted their target price on Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Finally, TD Cowen upped their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $130.65.

Gilead Sciences Stock Up 0.1%

Shares of NASDAQ GILD traded up $0.11 during trading on Monday, reaching $126.75. The company had a trading volume of 1,236,545 shares, compared to its average volume of 7,940,828. Gilead Sciences has a 12-month low of $88.57 and a 12-month high of $128.70. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The business’s 50-day moving average is $118.48 and its 200 day moving average is $113.75. The stock has a market cap of $157.26 billion, a PE ratio of 25.23, a P/E/G ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the previous year, the business posted $2.02 EPS. Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Deborah H. Telman sold 53,646 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the sale, the executive vice president directly owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. This represents a 55.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.23, for a total transaction of $313,075.00. Following the transaction, the chief financial officer directly owned 154,555 shares in the company, valued at $19,354,922.65. This represents a 1.59% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 125,146 shares of company stock worth $15,148,441. Corporate insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors have recently bought and sold shares of the business. One Wealth Advisors LLC lifted its position in Gilead Sciences by 34.8% during the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after purchasing an additional 2,364 shares during the last quarter. Ariel Investments LLC raised its position in shares of Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after buying an additional 30,630 shares in the last quarter. Simplify Asset Management Inc. lifted its holdings in shares of Gilead Sciences by 148.6% in the 2nd quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock valued at $5,864,000 after acquiring an additional 31,618 shares during the last quarter. Sivik Global Healthcare LLC lifted its holdings in shares of Gilead Sciences by 25.0% in the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $5,544,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Wealth Management Associates Inc. purchased a new position in Gilead Sciences in the second quarter worth about $255,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.